Listen to this Blog:  Your browser does not support audio. “It’s a dangerous business, Frodo, going out your door. You step onto the road, and if you don’t keep ... More

Listen to this Blog: Your browser does not support audio. Adapted from Best Practices in MSC Culture: Tracking & Reporting Cellular Age Using Population Doubling Level & Not Cell Passage ... More

Above, Fig. 1, the number and fraction of MSC trials and patients related to cells obtained via umbilical cord tissues has increased substantially over the last 10 years.  (SOURCE: celltrials.org).[1] ... More

“You mean, sit on top of a rocket and launched into space? Sounds dangerous; when do we go?” The Right Stuff (1983) Above, bar chart depicting estimated fraction of >500 ... More

Mesenchymal stem/stromal cells (MSCs) have been clinically translated broadly in the field of regenerative medicine and cellular immunotherapy. These cells possess inherent angiogenic, mitogenic, immunomodulatory, and anti-inflammatory functions, and they ... More

The environmental impact of hMSC manufacturing can be significantly reduced by switching from a process requiring media exchange to a batch culture process in a 10-layer vessel production process and ... More

Above, A Venn diagram showing MSCs at the convergence of major developments for the future of medicine. When MSCs are genome-edited, it will inevitably be done with cell therapy in ... More

Part II of a Blog Series on CQAs & CPPs. << Read Part I Mesenchymal stromal/stem cells (MSCs) have comprised the cellular source material for over 1,000 clinical trials worldwide ... More

Part I of a Blog Series on CQAs & CPPs Above, Diagram of current and proposed definitions to govern bioprocess development planning, conceived as a cycle with amplifying feedbacks, not ... More

Previously, we discussed estimating hMSC lot sizes for clinical manufacturing to develop an effective multi-year process development program. This exercise is crucial, because the calculated target cell lot size dictates ... More